Cargando…
Renin-angiotensin system inhibitors combined with cisplatin exacerbate cisplatin-induced nephrotoxicity in mice
INTRODUCTION: We previously reported that the concomitant use of enalapril and telmisartan exacerbates the risk of cisplatin (CDDP)-induced acute renal dysfunction compared to other antihypertensive drugs in mice. Thus, in the current study, we investigated the risk of developing chronic kidney dise...
Autores principales: | Tsuji, Takumi, Hosoda, Atsuki, Toriyama, Yuuki, Yoshida, Yuya, Kohno, Takeyuki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Neoplasia Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8857575/ https://www.ncbi.nlm.nih.gov/pubmed/35182957 http://dx.doi.org/10.1016/j.tranon.2022.101369 |
Ejemplares similares
-
Oral therapy for type 1 diabetes mellitus using a novel immunomodulator, FTY720 (fingolimod), in combination with sitagliptin, a dipeptidyl peptidase‐4 inhibitor, examined in non‐obese diabetic mice
por: Tsuji, Takumi, et al.
Publicado: (2012) -
A H(2)S Donor GYY4137 Exacerbates Cisplatin-Induced Nephrotoxicity in Mice
por: Liu, Mi, et al.
Publicado: (2016) -
Mechanisms of Cisplatin Nephrotoxicity
por: Miller, Ronald P., et al.
Publicado: (2010) -
Prevention of cisplatin nephrotoxicity
por: Hayati, Fatemeh, et al.
Publicado: (2015) -
Cisplatin-induced nephrotoxicity alters blood pressure response to angiotensin II administration in rats
por: Dehghani, Aghdas, et al.
Publicado: (2016)